These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 10744364

  • 1. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
    Gales AC, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):19-36. PubMed ID: 10744364
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.
    Gales AC, Jones RN, Andrade SS, Pereira AS, Sader HS.
    Braz J Infect Dis; 2005 Oct; 9(5):348-56. PubMed ID: 16410885
    [Abstract] [Full Text] [Related]

  • 3. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
    Biedenbach DJ, Beach ML, Jones RN.
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
    [Abstract] [Full Text] [Related]

  • 4. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936.
    Jones RN.
    Diagn Microbiol Infect Dis; 1999 Nov; 35(3):249-52. PubMed ID: 10626138
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS, Jones RN, Dowzicky MJ, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [Abstract] [Full Text] [Related]

  • 7. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
    Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
    [Abstract] [Full Text] [Related]

  • 8. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST) Group.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [Abstract] [Full Text] [Related]

  • 11. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.
    Projan SJ.
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):219S-223S; discussion 224S-228S. PubMed ID: 11001329
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S, Dowzicky MJ.
    Ann Clin Microbiol Antimicrob; 2017 Jul 12; 16(1):50. PubMed ID: 28701170
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS, Whitelaw A, Dowzicky MJ.
    Int J Antimicrob Agents; 2014 Feb 12; 43(2):170-8. PubMed ID: 24315313
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR, Kirby JT, Jones RN.
    Diagn Microbiol Infect Dis; 2004 Jul 12; 49(3):201-9. PubMed ID: 15246511
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul 12; 52(3):265-73. PubMed ID: 16105569
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
    Betriu C, Rodríguez-Avial I, Gómez M, Culebras E, López F, Alvarez J, Picazo JJ, Spanish Tigecycline Group.
    Diagn Microbiol Infect Dis; 2006 Dec 12; 56(4):437-44. PubMed ID: 16949245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.